Cargando…
A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy
Although high-dose methotrexate (HD-MTX) is the standard therapy for primary central nervous system lymphoma (PCNSL), the prognosis remains poor. Because 90% of PCNSL is diffuse large B-cell lymphoma (DLBCL), chimeric antigen receptor (CAR)-T cell therapy is expected to be beneficial. However, there...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japan Neurosurgical Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512489/ https://www.ncbi.nlm.nih.gov/pubmed/36238605 http://dx.doi.org/10.2176/jns-nmc.2022-0134 |
_version_ | 1784797849264848896 |
---|---|
author | MIZUTA, Ryo OTANI, Yoshihiro FUJII, Kentaro UNEDA, Atsuhito ISHIDA, Joji TANAKA, Takehiro IKEGAWA, Shuntaro FUJII, Nobuharu MAEDA, Yoshinobu DATE, Isao |
author_facet | MIZUTA, Ryo OTANI, Yoshihiro FUJII, Kentaro UNEDA, Atsuhito ISHIDA, Joji TANAKA, Takehiro IKEGAWA, Shuntaro FUJII, Nobuharu MAEDA, Yoshinobu DATE, Isao |
author_sort | MIZUTA, Ryo |
collection | PubMed |
description | Although high-dose methotrexate (HD-MTX) is the standard therapy for primary central nervous system lymphoma (PCNSL), the prognosis remains poor. Because 90% of PCNSL is diffuse large B-cell lymphoma (DLBCL), chimeric antigen receptor (CAR)-T cell therapy is expected to be beneficial. However, there are limited reports on CAR-T cell therapy for PCNSL because of the concern of neurotoxicity. Here, we report a case of relapsed PCNSL treated with anti-CD19 CAR-T cell therapy. A 40-year-old woman presenting with visual disturbance in her left eye was initially diagnosed with bilateral uveitis. Her histological diagnosis was DLBCL, and she was positive for CD19. Although she received chemotherapy including HD-MTX, the tumor relapsed in her right occipital lobe. She underwent remission induction therapy and then anti-CD19 CAR-T cell therapy. Cytokine release syndrome (CRS) grade 2 occurred, but there were no complications of CAR-T cell-related encephalopathy syndrome (CRES). She has achieved complete response for more than 1 year. Anti-CD19 CAR-T cell therapy is a revolutionary immunotherapy for treating relapsed or refractory (R/R) B lineage malignancies. Although there are concerns regarding CRS and CRES in central nervous system lymphoma, the use of anti-CD19 CAR-T cells to treat R/R PCNSL is safe and feasible. |
format | Online Article Text |
id | pubmed-9512489 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Japan Neurosurgical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-95124892022-10-12 A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy MIZUTA, Ryo OTANI, Yoshihiro FUJII, Kentaro UNEDA, Atsuhito ISHIDA, Joji TANAKA, Takehiro IKEGAWA, Shuntaro FUJII, Nobuharu MAEDA, Yoshinobu DATE, Isao NMC Case Rep J Case Report Although high-dose methotrexate (HD-MTX) is the standard therapy for primary central nervous system lymphoma (PCNSL), the prognosis remains poor. Because 90% of PCNSL is diffuse large B-cell lymphoma (DLBCL), chimeric antigen receptor (CAR)-T cell therapy is expected to be beneficial. However, there are limited reports on CAR-T cell therapy for PCNSL because of the concern of neurotoxicity. Here, we report a case of relapsed PCNSL treated with anti-CD19 CAR-T cell therapy. A 40-year-old woman presenting with visual disturbance in her left eye was initially diagnosed with bilateral uveitis. Her histological diagnosis was DLBCL, and she was positive for CD19. Although she received chemotherapy including HD-MTX, the tumor relapsed in her right occipital lobe. She underwent remission induction therapy and then anti-CD19 CAR-T cell therapy. Cytokine release syndrome (CRS) grade 2 occurred, but there were no complications of CAR-T cell-related encephalopathy syndrome (CRES). She has achieved complete response for more than 1 year. Anti-CD19 CAR-T cell therapy is a revolutionary immunotherapy for treating relapsed or refractory (R/R) B lineage malignancies. Although there are concerns regarding CRS and CRES in central nervous system lymphoma, the use of anti-CD19 CAR-T cells to treat R/R PCNSL is safe and feasible. The Japan Neurosurgical Society 2022-09-03 /pmc/articles/PMC9512489/ /pubmed/36238605 http://dx.doi.org/10.2176/jns-nmc.2022-0134 Text en © 2022 The Japan Neurosurgical Society https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives International License. |
spellingShingle | Case Report MIZUTA, Ryo OTANI, Yoshihiro FUJII, Kentaro UNEDA, Atsuhito ISHIDA, Joji TANAKA, Takehiro IKEGAWA, Shuntaro FUJII, Nobuharu MAEDA, Yoshinobu DATE, Isao A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy |
title | A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy |
title_full | A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy |
title_fullStr | A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy |
title_full_unstemmed | A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy |
title_short | A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy |
title_sort | case of relapsed primary central nervous system lymphoma treated with cd19-directed chimeric antigen receptor t cell therapy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512489/ https://www.ncbi.nlm.nih.gov/pubmed/36238605 http://dx.doi.org/10.2176/jns-nmc.2022-0134 |
work_keys_str_mv | AT mizutaryo acaseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT otaniyoshihiro acaseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT fujiikentaro acaseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT unedaatsuhito acaseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT ishidajoji acaseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT tanakatakehiro acaseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT ikegawashuntaro acaseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT fujiinobuharu acaseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT maedayoshinobu acaseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT dateisao acaseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT mizutaryo caseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT otaniyoshihiro caseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT fujiikentaro caseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT unedaatsuhito caseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT ishidajoji caseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT tanakatakehiro caseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT ikegawashuntaro caseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT fujiinobuharu caseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT maedayoshinobu caseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy AT dateisao caseofrelapsedprimarycentralnervoussystemlymphomatreatedwithcd19directedchimericantigenreceptortcelltherapy |